Clinical trials: Partial-onset Seizures
Seizures
Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy
This Phase 3 study is being conducted to evaluate the efficacy and safety of retigabine dosed at 900 mg/day and 600 mg/day, in three equally divided doses, compared with placebo in patients with epilepsy who are receiving up to…
- Trial name
- RESTORE2 (NCT00235755)
- Testing
- Retigabine
- Where
- 70 sites in United States, Australia and 11 more
- Volunteers
- 539 people
- Sponsor
- GlaxoSmithKline
Epilepsy, Partial
Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide
The purpose of the trial is to investigate whether changes in lipids and hormonal parameters can be observed in blood when Carbamazepine treatment is replaced with Lacosamide treatment, while Levetiracetam treatment remains…
- Trial name
- VICTOR (NCT01375374)
- Testing
- Lacosamide, Levetiracetam
- Where
- 7 sites in Austria, Germany and 1 more
- Volunteers
- 11 people
- Sponsor
- UCB Pharma
Highly Drug-resistant Focal Epilepsy
An Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy
The purpose of study EP0073 is to assess the long-term safety, tolerability, and efficacy during 5 years of treatment with the drug UCB0942 in patients with highly drug-resistant focal epilepsy.
- Trial name
- NCT02625090
- Testing
- UCB0942
- Where
- 15 sites in Belgium, Bulgaria and 4 more
- Volunteers
- 42 people
- Sponsor
- UCB Biopharma SRL
Epilepsy
Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097
This Phase 3 trial is an open-label extension study of the placebo-controlled, double-blind VRX-RET-E22-302 trial. Patients who have completed the VRX-RET-E22-302 trial and who meet inclusion and exclusion criteria will be…
- Trial name
- NCT00310388
- Testing
- Retigabine (INN), Ezogabine (USAN)
- Where
- 67 sites in Australia, Belgium and 10 more
- Volunteers
- 376 people
- Sponsor
- GlaxoSmithKline
Epilepsy; Paediatric Partial Onset Seizures
Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Study)
The purpose of this study is to compare the safety and efficacy of zonisamide with placebo.
- Trial name
- NCT00566254
- Testing
- Zonisamide
- Where
- 43 sites in Belgium, Estonia and 7 more
- Volunteers
- 207 people
- Sponsor
- Eisai Inc.
Seizures
A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
The goal of this clinical trial is to learn if CVL-865, when taken regularly with other anti-seizure medicines, works to prevent seizures in adults with drug-resistant focal onset seizures.
- Trial name
- NCT04244175
- Testing
- CVL-865
- Where
- 76 sites in United States, Australia and 5 more
- Volunteers
- 154 people
- Sponsor
- AbbVie
Partial Epilepsies, Partial Onset Seizures
Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures
The purpose of the trial is to evaluate the safety of intravenous (iv) lacosamide delivered in a single dose followed by 6.5 days of oral lacosamide treatment in subjects with partial-onset seizures.
- Trial name
- NCT00655551
- Testing
- lacosamide
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Epilepsy
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
The purpose of this study is to evaluate the safety and tolerability of long-term therapy with retigabine administered as adjunctive therapy in adult epilepsy patients with partial-onset seizures, who completed the…
- Trial name
- NCT00310375
- Testing
- Ezogabine: USAN Retigabine (International Nonproprietary Name)
- Where
- 51 sites in United States, Argentina and 3 more
- Volunteers
- 181 people
- Sponsor
- GlaxoSmithKline
Epilepsies, Partial
A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures
This study is planned to evaluate the safety and efficacy of L059 (levetiracetam) in long-term administration in patients who completed N01020 [NCT00160165] or N01221 [NCT00280696].
- Trial name
- NCT00367432
- Testing
- Levetiracetam
- Where
- 53 sites in Japan
- Volunteers
- 398 people
- Sponsor
- UCB Japan Co. Ltd.
Drug Resistant Partial Onset Seizure
Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension
The study will evaluate the effectiveness and safety of an investigational drug-ganaxolone - on partial seizure frequency in adults with epilepsy taking a maximum of 3 antiepileptic medications (AEDs).
- Trial name
- NCT01963208
- Testing
- ganaxolone
- Where
- 71 sites in United States, Australia and 4 more
- Volunteers
- 405 people
- Sponsor
- Marinus Pharmaceuticals
Partial Onset Seizures
A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.
This study is designed to evaluate the effectiveness of 2 doses of pregabalin to reduce seizure frequency as an add on therapy in pediatric subjects 1 month to <4 years of age with refractory partial onset seizures.
- Trial name
- NCT02072824
- Testing
- Pregabalin Dose Level 1, Pregabalin Dose Level 2
- Where
- 72 sites in United States, Belarus and 21 more
- Volunteers
- 175 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Epilepsy
Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients
This is an open Label study to investigate the safety and efficacy of eslicarbazepine acetate as adjunctive therapy for partial seizures in elderly patients.
- Trial name
- NCT01422720
- Testing
- Eslicarbazepine Acetate
- Where
- 48 sites in Austria, Bulgaria and 8 more
- Volunteers
- 72 people
- Sponsor
- Bial - Portela C S.A.
Epilepsy, Partial
Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy
Community based study assessing safety and efficacy of levetiracetam in partial onset seizures. The optimal dose in daily clinical practice will be used.
- Trial name
- NCT00160654
- Testing
- Levetiracetam
- Where
- 29 sites in Hong Kong, Malaysia and 4 more
- Volunteers
- 251 people
- Sponsor
- UCB Pharma
Epilepsy, Partial Seizures
A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years
Study A0081041 is a double blind, placebo controlled, randomized, parallel group, multicenter study to evaluate the safety and efficacy of two dose levels of pregabalin administered in equally divided daily doses, in either…
- Trial name
- PERIWINKLE (NCT01389596)
- Testing
- Pregabalin add-on therapy
- Where
- 86 sites in United States, Belgium and 16 more
- Volunteers
- 295 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Tuberous Sclerosis Complex-associated Refractory Seizures
A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures
This study evaluated the efficacy and safety of two trough-ranges of everolimus given as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who had refractory partial-onset seizures.
- Trial name
- EXIST-3 (NCT01713946)
- Testing
- RAD001, Antiepileptic drug (1 to 3 only), open label RAD001 (only used for post-extension phase)
- Where
- 104 sites in United States, Argentina and 23 more
- Volunteers
- 366 people
- Sponsor
- Novartis Pharmaceuticals
Epilepsy
Conversion to Monotherapy Study With Keppra XR for Partial Seizures
The primary objective of this study is to assess the efficacy of two doses of Keppra XR compared with a historical control as the placebo, in the monotherapy treatment of partial onset seizures.
- Trial name
- NCT00419094
- Testing
- Keppra XR
- Where
- 45 sites in United States, Mexico and 2 more
- Volunteers
- 228 people
- Sponsor
- UCB Pharma
Epilepsy, Partial
Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures
This trial will evaluate the efficacy and safety of ucb 44212 as add on therapy in subjects with focal epilepsy.
- Trial name
- NCT00152451
- Testing
- Seletracetam (ucb 44212)
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- UCB S.A. - Pharma Sector
Refractory Partial Seizures
Evaluating Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
The purpose of this study is to evaluate the efficacy, safety and tolerability of perampanel when given as an adjunctive therapy in subjects with refractory partial seizures.
- Trial name
- NCT00700310
- Testing
- perampanel
- Where
- 137 sites in Australia, Bulgaria and 21 more
- Volunteers
- 712 people
- Sponsor
- Eisai Inc.
Partial Epilepsy
A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
This is a multicenter, double-blind, randomized, placebo-controlled dose response study, with an 8-week prospective baseline and an 18 week double-blind treatment period (including a 6-week titration phase and 12 week maintenance…
- Trial name
- NCT01866111
- Testing
- YKP3089
- Where
- 67 sites in United States, Australia and 13 more
- Volunteers
- 437 people
- Sponsor
- SK Life Science, Inc.
Epilepsy
Levetiracetam: The Anti-Convulsant of Choice for Elderly Patients With Dementia
Elderly persons with dementia are at risk for seizures, however, traditional anticonvulsants are poorly tolerated in this population. Our goal is to examine Levetiracetam (Keppra) in elderly dementia patients with seizures.
- Trial name
- NCT01318408
- Testing
- Levetiracetam
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Drexel University College of Medicine